Stock comparison
Ironwood Pharmaceuticals
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IRWD
Ironwood Pharmaceuticals
Market cap
$645.28M
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IRWD | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 47D | 71B | UTHR |
| Benjamin Graham | 25F | 76B | UTHR |
| Philip Fisher | 41D | 76B | UTHR |
| Peter Lynch | 26F | 62C | UTHR |
| Joel Greenblatt | 69B | 46D | IRWD |
| Charlie Munger | 68D | 64C | IRWD |
| Terry Smith | 66C | 64C | IRWD |
Side-by-side metrics
| Metric | IRWD | UTHR |
|---|---|---|
| Market cap | $645.28M | $24.13B |
| P/E (TTM) | 4.5x | 19.2x |
| EV/EBIT | 9.0x | 15.2x |
| ROIC (TTM) | 43.86% | 18.81% |
| Gross margin | 99.75% | 86.58% |
| Net margin | 41.76% | 40.61% |
| Revenue CAGR 5y | -8.02% | 17.22% |
| EPS CAGR 5y | -53.69% | 29.84% |
| Debt / Equity | - | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IRWD leads on
- Debt / Equity-vs -+100%
- P/E (TTM)4.5xvs 19.2x+77%
- ROIC (TTM)43.86%vs 18.81%+57%
- EV/EBIT9.0xvs 15.2x+41%
UTHR leads on
- EPS CAGR 5y29.84%vs -53.69%+156%
- Revenue CAGR 5y17.22%vs -8.02%+147%
- Market cap$24.13Bvs $645.28M+97%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.